Search

Your search keyword '"Katz, Jeffrey"' showing total 487 results
Start Over Author "Katz, Jeffrey" Publication Year Range Last 3 years
487 results on '"Katz, Jeffrey"'

7. Multivariable Modeling of Biomarker Data From the Phase I Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium

Author

Hunter, David J, Deveza, Leticia A, Collins, Jamie E, Losina, Elena, Katz, Jeffrey N, Nevitt, Michael C, Lynch, John A, Roemer, Frank W, Guermazi, Ali, Bowes, Michael A, Dam, Erik B, Eckstein, Felix, Kwoh, C Kent, Hoffmann, Steve, and Kraus, Virginia B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Biomedical Imaging, Pain Research, Arthritis, Aging, Chronic Pain, Clinical Research, Musculoskeletal, Biomarkers, Cartilage, Articular, Disease Progression, Humans, Knee Joint, Magnetic Resonance Imaging, National Institutes of Health (U.S.), Osteoarthritis, Knee, Synovitis, United States, Public Health and Health Services, Psychology, Clinical sciences, Allied health and rehabilitation science
Abstract

ObjectiveTo determine the optimal combination of imaging and biochemical biomarkers for use in the prediction of knee osteoarthritis (OA) progression.MethodsThe present study was a nested case-control trial from the Foundation of the National Institutes of Health OA Biomarkers Consortium that assessed study participants with a Kellgren/Lawrence grade of 1-3 who had complete biomarker data available (n = 539 to 550). Cases were participants' knees that had radiographic and pain progression between 24 and 48 months compared to baseline. Radiographic progression only was assessed in secondary analyses. Biomarkers (baseline and 24-month changes) that had a P value of

Published
2022

10. DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation

Author

Kwon, Youngho, Rösner, Heike, Zhao, Weixing, Selemenakis, Platon, He, Zhuoling, Kawale, Ajinkya S., Katz, Jeffrey N., Rogers, Cody M., Neal, Francisco E., Badamchi Shabestari, Aida, Petrosius, Valdemaras, Singh, Akhilesh K., Joel, Marina Z., Lu, Lucy, Holloway, Stephen P., Burma, Sandeep, Mukherjee, Bipasha, Hromas, Robert, Mazin, Alexander, Wiese, Claudia, Sørensen, Claus S., and Sung, Patrick

Published
2023
Full Text
View/download PDF

13. The osteoarthritis prevention study (TOPS) - A randomized controlled trial of diet and exercise to prevent Knee Osteoarthritis: Design and rationale

Author

Messier, Stephen P., Callahan, Leigh F., Losina, Elena, Mihalko, Shannon L., Guermazi, Ali, Ip, Edward, Miller, Gary D., Katz, Jeffrey N., Loeser, Richard F., Pietrosimone, Brian G., Soto, Sandra, Cook, James L., Newman, Jovita J., DeVita, Paul, Spindler, Kurt P., Runhaar, Jos, Armitano-Lago, Cortney, Duong, Vicky, Selzer, Faith, Hill, Ryan, Love, Monica, Beavers, Daniel P., Saldana, Santiago, Stoker, Aaron M., Rice, Paige E., and Hunter, David J.

Published
2024
Full Text
View/download PDF

19. Dog Olfactory Cognition

Author

Davila, Adam, Smith, Jordan G., Cox, Emma, Montgomery, Lane, Krichbaum, Sarah, Lazarowski, Lucia, Katz, Jeffrey S., and Lazarowski, Lucia, editor

Published
2023
Full Text
View/download PDF

29. A STRUCTURAL EQUATIONS MODEL OF EMOTIONAL INTELLIGENCE AND RESPONSES TO THE COVID-19 PANDEMIC

Author

Rahim, M. Afzalur, Yates, Mariah, Katz, Jeffrey, and Civelek, Ismail

Subjects
Business, World Health Organization
Abstract

This study investigates the relationship between an ability-based measure of emotional intelligence (EI) and responses to the COVID-19 virus (RCV) of employed students at a university in the United States. We test our model with questionnaire data from 143 participants. Data analysis including confirmatory factor analysis and structural equation modeling using LISREL suggests that EI is positively associated with RCV. Implications for management, directions for future research, and limitations of the study are discussed. Keywords: Intelligence, Emotional intelligence, Non-cognitive intelligence, Responses to COVID-19, INTRODUCTION The coronavirus 2019 (COVID-19) is a contagious disease initially discovered in Wuhan, China in December 2019 (CDC, 2021). Due to the highly contagious nature of COVID-19, the World Health [...]

Published
2022

37. Same/Different Learning

Author

Wright, Anthony A., Katz, Jeffrey S., Kelly, Debbie M., Clary, Dawson, Section editor, Vonk, Jennifer, editor, and Shackelford, Todd K., editor

Published
2022
Full Text
View/download PDF

49. Thrombectomy for Stroke With Large Infarct on Noncontrast CT: The TESLA Randomized Clinical Trial.

Author

Yoo, Albert J., Zaidat, Osama O., Sheth, Sunil A., Rai, Ansaar T., Ortega-Gutierrez, Santiago, Given II, Curtis A., Zaidi, Syed F., Grandhi, Ramesh, Cuellar, Hugo, Mokin, Maxim, Katz, Jeffrey M., Alshekhlee, Amer, Taqi, Muhammad A., Ansari, Sameer A., Siddiqui, Adnan H., Barazangi, Nobl, English, Joey D., Maud, Alberto, Kirmani, Jawad, and Gupta, Rishi

Abstract

Key Points: Question: Does endovascular thrombectomy improve functional outcome in patients with a large infarct on noncontrast computed tomographic (CT) scan within 24 hours of stroke onset? Findings: In this randomized trial of 300 patients, thrombectomy did not significantly improve 90-day functional outcome compared with medical management alone for the primary end point (adjusted difference in utility-weighted modified Rankin Scale score, 0.63). Meaning: Among patients with large infarct detected by noncontrast CT and presenting within 24 hours, thrombectomy did not significantly improve functional outcome at 90 days. Importance: Recent large infarct thrombectomy trials used heterogeneous imaging modalities and time windows for patient selection. Noncontrast computed tomographic (CT) scan is the most common stroke imaging approach. It remains uncertain whether thrombectomy is effective for patients with large infarcts identified using noncontrast CT alone within 24 hours of stroke onset. Objective: To evaluate the effect of thrombectomy in patients with a large infarct on a noncontrast CT scan within 24 hours of onset. Design, Setting, and Participants: Open-label, blinded–end point, bayesian-adaptive randomized trial with interim analyses for early stopping (futility or success) or population enrichment, which was conducted at 47 US academic and community-based stroke thrombectomy centers. Three hundred patients presenting within 24 hours with anterior-circulation, large-vessel occlusion and large infarct on noncontrast CT scan, with Alberta Stroke Program Early CT Scores of 2 to 5, were randomized to undergo thrombectomy or usual care. Enrollment occurred July 16, 2019 to October 17, 2022; final follow-up, January 25, 2023. Intervention: The intervention patients (n = 152) underwent endovascular treatment using standard thrombectomy devices and usual medical care. Control patients (n = 148) underwent usual medical care alone. Main Outcomes and Measures: The primary efficacy end point was improvement in 90-day functional outcome measured using mean utility-weighted modified Rankin Scale (UW-mRS) scores (range, 0 [death or severe disability] to 10 [no symptoms]; minimum clinically important difference, 0.3). A bayesian model determined the posterior probability that the intervention would be superior to usual care; statistical significance was a 1-sided posterior probability of.975 or more. The primary adverse event end point was 90-day mortality; secondary adverse event end points included symptomatic intracranial hemorrhage and radiographic intracranial hemorrhage. Results: The trial enrolled 300 patients (152 intervention, 148 control; 138 females [46%]; median age, 67 years), without early stopping or enrichment; 297 patients completed the 90-day follow-up. The mean (SD) 90-day UW-mRS score was 2.93 (3.39) for the intervention group vs 2.27 (2.98) for the control group with an adjusted difference of 0.63 (95% credible interval [CrI], −0.09 to 1.34; posterior probability for superiority of thrombectomy,.96). The 90-day mortality was similar between groups: 35.3% (53 of 150) for the intervention group vs 33.3% (49 of 147) for the control group. Six of 151 patients (4.0%) in the intervention group and 2 of 149 (1.3%) in the control group experienced 24-hour symptomatic intracranial hemorrhage. Fourteen patients of 148 (9.5%) in the intervention group vs 4 of 146 (2.7%) in the control group experienced parenchymal hematoma type 1 hemorrhages; 14 (9.5%) in the intervention group vs 5 (3.4%) in the control group experienced parenchymal hematoma type 2 hemorrhages; and 24 (16.2%) in the intervention group vs 9 (6.2%) in the control group experienced subarachnoid hemorrhages. Conclusions and Relevance: Among patients with a large infarct on noncontrast CT within 24 hours, thrombectomy did not demonstrate improvement in functional outcomes. But the width of the credible interval around the effect estimate includes the possibility of both no important effect and a clinically relevant benefit, so the potential role of thrombectomy with this imaging approach and time window will likely require additional study. Trial Registration: ClinicalTrials.gov Identifier: NCT03805308 This clinical trial evaluates whether endovascular thrombectomy and usual medical care vs medical care alone improves functional outcomes among patients who present within 24 hours after symptom onset with anterior-circulation, large-vessel occlusion, and large infarct detected by noncontrast CT scan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results